The Commissioner is authorized to charge the requisite fee for small entity to the Deposit Account No. 23-1703.

## **REMARKS**

Claims 1-16 are pending. Applicants request reconsideration of the restriction requirement, wherein the single invention has been divided by the Examiner t9 three groups of claims:

- I. Claims 1-6, 8-12, and 15-16 drawn to synthetic immunogens for inducing specific antibody against GnRH comprising a fusion peptide comprising a promiscuous helper T-cell peptide epitope and immunomimic peptide and a pharmaceutical injectable composition;
- II. Claims 7 and 13, drawn to a method of inducing immune response against GnRH in an animal; and
- III. Claim 14 drawn to a method of producing an anti-GnRH immune response inducing fusion peptide immunogen comprising preparing a chimeric peptide.

In addition, the Examiner requires election of a single disclosed species for prosecution of generic claims 1, 7, and 14.

Applicant provisionally elects present prosecution of Group I claims 1-6, 8-12, and 15-16, while reserving the right to posecute the Groups II and III claims in a separate, divisional patent application.

In addition, pursuant to the Examiner's requirement, Applicant provisionally elects synthetic peptide 3 (Sequence ID NO: 11) using immunogenic tetanus toxoid aa sequence 830-844 in the amino terminal end in continuation through the peptide spacer, GPSL to the GnRH immunomimic peptide.

The elected spacer is a synthetic peptide as in SEQ ID NO: 5 of the Sequence Listing.

1102865-0047

The Applicant, however, traverses this requirement as unduly restrictive in view of the design around peptide constructions or variations which may circumvent the patent scope of this invention. In traverse, Applicant requests the Examiner's reconsideration and withdrawal of the restriction requirement, especially the additional limitation as to species embodiment. The prosecution of more than one application or possibly as many as twelve applications of this invention for the full patent protection would place undue hardship on the inventors as well as the public, due to substantial additional search filing and examination costs.

The Applicant reserves the right to prosecute the other claim groupings by another divisional application.

The Commissioner is authorized to charge any fees in connection with this response to Deposit Account 23-1703.

Dated: July 26, 2002

Respectfully submitted,

Hans-Peter G. Hoffmann, Ph.D.

Reg. No. 37,352 Agent for Applicant

Have toked

Customer No. 007470

Agent's Direct Dial: (212) 819-8840

**Enclosure**